---
schema_version: "secwatch.filing_event.v1"
accession: "0001701541-21-000038"
form_type: "8-K"
ticker: "BDTX"
cik: "0001701541"
company_name: "Black Diamond Therapeutics, Inc."
filed_at: "2021-11-08T23:59:59+00:00"
generated_at: "2026-06-28T11:36:43.162983+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Black Diamond Therapeutics Q3 2021 cash $235M; BDTX-189 Phase 2 on track for year-end

## Summary
- Cash, equivalents, and investments $235.0M as of Sept 30, 2021; expected runway into H2 2023.
- Net cash used in operations Q3 2021 was $26.5M, up from $11.5M in Q3 2020.
- R&D expenses $27.6M (Q3 2021) vs $12.9M (Q3 2020), driven by headcount and preclinical/clinical costs.
- BDTX-189 Phase 2 portion initiation by end of 2021; BDTX-1535 IND filing targeted H1 2022.
- Preclinical data for BDTX-1535, BRAF, and FGFR programs presented at ANE conference; partnership with OpenEye Scientific.

## SEC filing metadata
- accession: 0001701541-21-000038
- form_type: 8-K
- ticker: BDTX
- cik: 0001701541
- company_name: Black Diamond Therapeutics, Inc.
- filed_at: 2021-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701541/000170154121000038/0001701541-21-000038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701541/000170154121000038/bdtx-20211108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001701541-21-000038
- JSON: https://secwatch.observer/filing/0001701541-21-000038.json
- Plain text: https://secwatch.observer/filing/0001701541-21-000038.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.